Oxford Nanopore Technologies Plc (ONTTF)

$1.96 +0.03 (1.52%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 9,000
Avg Vol 14,278
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company also provides PromethION 2 Solo, PromethION 2, PromethION...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 84 5034 7900
Fax: 44 84 5034 7901
Address:
Gosling Building, Edmund Halley Road Oxford Science Park, Oxford, United Kingdom
Marlig
Marlig May. 21 at 7:27 AM
$ONTTF Breakthrough genetic test diagnoses brain tumors in just two hours is based on Oxford Nanopore's devices and technology. To be rolled out across the UK's National Health Trusts. Source: https://bioengineer.org/breakthrough-genetic-test-diagnoses-brain-tumors-in-just-two-hours/
0 · Reply
Amir1995
Amir1995 Mar. 5 at 8:10 AM
$ONTTF Seems like BGI Genomics is using nanopore tech now and will be the next big thing.. Oxford Nanopore just couldn’t convert and lost all momentum
0 · Reply
Mogden70
Mogden70 Jan. 29 at 12:07 PM
$ONTTF I’m out. Too slow and too illiquid. Not going to attract proper institutional demand any time soon.
0 · Reply
BullishMantra
BullishMantra Dec. 6 at 6:23 AM
$ONTTF watching this… hoping itll start the explosive journey soon
1 · Reply
Mogden70
Mogden70 Dec. 3 at 2:51 PM
$ONTTF Oxford Nanopore is going into the FTSE 250 according to FTSE Russell. They have also announced a partnership with UK Biobank for an "epigenetic dataset targeting the causes of cancer, dementia, complex disease." Financial backers of Biobank include Eric Schmidt and Ken Griffin. No impact on 2024, but supports the incremental revenue growth target of over 30% constant growth y-on-y between 2024 and 2027.
0 · Reply
Mogden70
Mogden70 Oct. 25 at 1:44 PM
$ONTTF up 75% in the last six months, and nobody is talking or interested in this stock.
0 · Reply
Mogden70
Mogden70 Jul. 26 at 4:01 PM
$ONTTF (Bloomberg) -- Oxford Nanopore shares climb as much as 4.2% after the British DNA-sequencing company said financial performance in the first-half of the year was in line with expectations. Analysts see Wednesday’s update alleviating concerns. ANALYST COMMENTARY Citi (buy) * The 1H revenue performance along with management commentary on improving growth trends is “somewhat better-than-expected,” analyst Veronika Dubajova writes in a note
0 · Reply
Mogden70
Mogden70 Jul. 9 at 1:51 AM
$ONTTF Hopefully someone agrees with that and decides to take them over on the cheap.
0 · Reply
MagisterofMarkets
MagisterofMarkets Jun. 25 at 4:21 PM
$ONTTF listing on LSX was their biggest mistake
0 · Reply
Marlig
Marlig Jun. 4 at 6:51 PM
$ONTTF AGM on the 10th June
0 · Reply
Latest News on ONTTF
No data available.
Marlig
Marlig May. 21 at 7:27 AM
$ONTTF Breakthrough genetic test diagnoses brain tumors in just two hours is based on Oxford Nanopore's devices and technology. To be rolled out across the UK's National Health Trusts. Source: https://bioengineer.org/breakthrough-genetic-test-diagnoses-brain-tumors-in-just-two-hours/
0 · Reply
Amir1995
Amir1995 Mar. 5 at 8:10 AM
$ONTTF Seems like BGI Genomics is using nanopore tech now and will be the next big thing.. Oxford Nanopore just couldn’t convert and lost all momentum
0 · Reply
Mogden70
Mogden70 Jan. 29 at 12:07 PM
$ONTTF I’m out. Too slow and too illiquid. Not going to attract proper institutional demand any time soon.
0 · Reply
BullishMantra
BullishMantra Dec. 6 at 6:23 AM
$ONTTF watching this… hoping itll start the explosive journey soon
1 · Reply
Mogden70
Mogden70 Dec. 3 at 2:51 PM
$ONTTF Oxford Nanopore is going into the FTSE 250 according to FTSE Russell. They have also announced a partnership with UK Biobank for an "epigenetic dataset targeting the causes of cancer, dementia, complex disease." Financial backers of Biobank include Eric Schmidt and Ken Griffin. No impact on 2024, but supports the incremental revenue growth target of over 30% constant growth y-on-y between 2024 and 2027.
0 · Reply
Mogden70
Mogden70 Oct. 25 at 1:44 PM
$ONTTF up 75% in the last six months, and nobody is talking or interested in this stock.
0 · Reply
Mogden70
Mogden70 Jul. 26 at 4:01 PM
$ONTTF (Bloomberg) -- Oxford Nanopore shares climb as much as 4.2% after the British DNA-sequencing company said financial performance in the first-half of the year was in line with expectations. Analysts see Wednesday’s update alleviating concerns. ANALYST COMMENTARY Citi (buy) * The 1H revenue performance along with management commentary on improving growth trends is “somewhat better-than-expected,” analyst Veronika Dubajova writes in a note
0 · Reply
Mogden70
Mogden70 Jul. 9 at 1:51 AM
$ONTTF Hopefully someone agrees with that and decides to take them over on the cheap.
0 · Reply
MagisterofMarkets
MagisterofMarkets Jun. 25 at 4:21 PM
$ONTTF listing on LSX was their biggest mistake
0 · Reply
Marlig
Marlig Jun. 4 at 6:51 PM
$ONTTF AGM on the 10th June
0 · Reply
Mogden70
Mogden70 May. 21 at 12:30 AM
$ONTTF Anyone heard anything about a management conference call with U.K. based investors today or tomorrow?
0 · Reply
Yourmatefromdownunder
Yourmatefromdownunder Mar. 13 at 5:30 PM
$ONTTF Great buy right now, hold this for two years you’ll be laughing!
1 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 10:55 AM
$ONTTF Oxford Nanopore, SeqOne partner for interpretation of nanopore sequencing Oxford Nanopore Technologies announced a new partnership enabling end-to-end analytical workflows from sample to report, focusing on rare diseases in the short-term and oncology in the longer-term. Available, SeqOne's platform germVar enables AI-enhanced whole genome variant interpretation from Oxford Nanopore EPI2ME, currently for research use only. SeqOne's germVar WGS offers precise and comprehensive variant analysis for single and family cases within an advanced and intuitive interpretation hub. Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy. It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
0 · Reply
Yourmatefromdownunder
Yourmatefromdownunder Feb. 28 at 3:29 PM
$ONTTF Adding more shares, if you have int trading it’s ONT in London. Grab this while it’s cheap and hold long term.
0 · Reply
MagisterofMarkets
MagisterofMarkets Feb. 28 at 2:06 PM
$ONTTF just applied for a job, hopefully I can get it and also get an opportunity for stock based incentives so I don’t have to continue paying transaction fees lol
0 · Reply
CyanideHCN
CyanideHCN Feb. 8 at 3:35 PM
$QSI started as a single molecule long read DNA sequencing company. The technology appears competitive against $PACB and $ONTTF and likely $ILMN. Deploy it first as a proteomics platform and then get even more pull through with long read DNA sequencing. Love it
2 · Reply
MagisterofMarkets
MagisterofMarkets Feb. 1 at 3:48 PM
$ONTTF damn I should’ve just paid the $50 transaction fee
0 · Reply
MagisterofMarkets
MagisterofMarkets Jan. 29 at 4:56 PM
$ONTTF if i didn’t have to pay a $50 transaction fee id be buying this up rn
1 · Reply
Yourmatefromdownunder
Yourmatefromdownunder Sep. 29 at 2:20 PM
$ONTTF Nice! Bagged this one cheap a few weeks back. Great long term buy, great company. Even with today’s move it’s a bargain.
0 · Reply